Does Social Prescribing Actually Reduce Loneliness?

Since 2018, “social prescribing” has become the standard policy answer to loneliness in the UK, cited approvingly in national strategy and increasingly proposed elsewhere. The mechanism is simple: a GP or link worker refers a patient to a non-clinical activity, a walking group, an art class, a befriending scheme, on the theory that structured social contact will reduce isolation and loneliness and, downstream, cut demand on health services. The UK’s 2018 strategy, A Connected Society, made social prescribing a central plank of national loneliness policy and funded link workers to deliver it. The question this piece asks is narrower than whether social prescribing sounds sensible. It is whether the trial evidence actually shows that it reduces loneliness, as opposed to something adjacent to loneliness.

The answer, on the evidence available, is not really.

What the two systematic reviews actually found

Two systematic reviews published in 2021 looked directly at this question. A review in the International Journal of Environmental Research and Public Health examined social prescribing’s effect on individual and community wellbeing broadly, and reported increases in self-esteem and self-confidence as the key outcomes documented across the studies it covered. Self-esteem and self-confidence are plausible correlates of reduced loneliness. They are not loneliness. The review’s authors also noted limited trial evidence and heterogeneity across programmes, which is a polite way of saying that the studies being pooled were not measuring the same thing with the same rigor.

A second review, published in Perspectives in Public Health and focused specifically on loneliness, found that all nine included studies reported positive individual impacts, and three reported reductions in use of GP, emergency, social worker, or inpatient services. That sounds like a stronger result. But “positive individual impacts” is a broad basket, and the review does not claim that all nine studies used a validated loneliness instrument, or that reductions in service use were causally linked to reduced loneliness rather than to other effects of the referral, such as simply having more contact with a link worker who could address unrelated problems. Nine studies is also a small evidence base on which to build a national policy, and the review does not report the study designs in enough detail to say how many were randomised as opposed to observational, before-and-after evaluations of a single programme.

This is the recurring problem with social prescribing research: it measures what programmes happen to have measured, which is often wellbeing, self-esteem, or service utilization, rather than loneliness itself, assessed with an instrument like the UCLA Loneliness Scale that would make results comparable across studies and to the wider literature. AARP’s 2018 survey of adults 45 and older used the 20-item UCLA scale and found that a third of respondents were lonely, with the size and diversity of a person’s social network as the strongest predictor. That is the kind of instrument that would let a social prescribing trial say something comparable. Neither 2021 review indicates that this was standard practice across the studies it pooled.

Why the National Academies were more cautious

The National Academies’ 2020 consensus report on social isolation and loneliness in older adults, which found that roughly a quarter of adults 65 and older are socially isolated, called for the health care system to routinely assess isolation and loneliness. That is a call for measurement, not a call for social prescribing specifically. A clinician-facing commentary on the report published later in 2020 pushed on exactly this gap: it argued for routine assessment in clinical settings but spent considerable attention on what that would actually require in practice, implying the infrastructure for reliable assessment, let alone reliable intervention, is not yet built. Neither document endorses social prescribing as a proven remedy. Both treat the identification problem as harder and more urgent than the intervention problem, which is a notably different emphasis than the one that has driven UK policy.

The stakes of getting this wrong

This is not a low-stakes measurement quibble. Holt-Lunstad’s 2015 meta-analysis in Perspectives on Psychological Science found that social isolation carries an odds ratio of 1.29 for early mortality, loneliness 1.26, and living alone 1.32, effects that held after adjusting for health status and were more predictive of death in samples averaging under 65. If a national strategy is going to spend public money on an intervention aimed at these outcomes, the intervention’s evaluation should be measuring the same constructs the mortality literature uses. At present it largely is not. A programme that raises self-esteem may or may not touch the isolation and loneliness that the mortality studies are tracking, and the difference matters for whether social prescribing belongs in the same conversation as smoking cessation or exercise, the framing that a 2021 review in the American Journal of Lifestyle Medicine explicitly proposed for social connection more broadly.

What would settle this

A trial that would actually answer the policy question would need three things the current literature mostly lacks: a validated loneliness or isolation instrument administered before and after referral, a comparison group that did not receive the referral, and follow-up long enough to distinguish a short-term boost in contact from a durable change in someone’s social network. None of the reviews cited above describe a body of research meeting all three conditions consistently. Until one does, the honest description of social prescribing is that it is a plausible, low-cost, popular intervention with encouraging but methodologically thin support, not a proven remedy for loneliness as that term is used in the epidemiological literature. Continuing to fund it is defensible as a bet. Describing it as evidence-based, in the sense the mortality and prevalence research uses that phrase, is not yet accurate.